These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15100330)
1. Dual purpose: some cancer therapies used to treat autoimmune diseases. Ben-Ari ET J Natl Cancer Inst; 2004 Apr; 96(8):577-9. PubMed ID: 15100330 [No Abstract] [Full Text] [Related]
2. [Rituximab and autoimmune disorders therapy]. Quint L Rev Med Interne; 2004 Oct; 25(10):752-4. PubMed ID: 15471601 [TBL] [Abstract][Full Text] [Related]
3. Clinical advances in therapies targeting the interleukin-2 receptor. Church AC QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007 [No Abstract] [Full Text] [Related]
6. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. Waldmann TA J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565 [TBL] [Abstract][Full Text] [Related]
7. The use of monoclonal antibodies in immune-mediated hematologic disorders. Dierickx D; Beke E; Devos T; Delannoy A Med Clin North Am; 2012 May; 96(3):583-619, xi. PubMed ID: 22703857 [TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Chamberlain MC Neurology; 2015 Feb; 84(7):758-9. PubMed ID: 25688152 [No Abstract] [Full Text] [Related]
9. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects]. ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in cancer therapy: 25 years of progress. Oldham RK; Dillman RO J Clin Oncol; 2008 Apr; 26(11):1774-7. PubMed ID: 18398141 [No Abstract] [Full Text] [Related]
11. [Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis]. Sastre-Garriga J; Montalban X Neurologia; 2011 Nov; 26(9):556-62. PubMed ID: 21481981 [TBL] [Abstract][Full Text] [Related]
12. Scientists recall progress and promise of translational research. Marwick C J Natl Cancer Inst; 2001 Jan; 93(1):13-5. PubMed ID: 11136835 [No Abstract] [Full Text] [Related]
13. Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. Pan S; Yu H; Surti A; Cheng I; Marks SD; Brogan PA; Eleftheriou D; Standing JF Br J Clin Pharmacol; 2019 Aug; 85(8):1790-1797. PubMed ID: 31026092 [TBL] [Abstract][Full Text] [Related]
14. New monoclonal antibodies to prevent transplant rejection. Med Lett Drugs Ther; 1998 Sep; 40(1036):93-4. PubMed ID: 9774964 [No Abstract] [Full Text] [Related]
16. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). Graves JE; Nunley K; Heffernan MP J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618 [TBL] [Abstract][Full Text] [Related]
17. Treating immunobullous diseases: an update. Reynaert S; Black MM Dermatol Nurs; 2004 Feb; 16(1):29-34, 70. PubMed ID: 15022502 [TBL] [Abstract][Full Text] [Related]
18. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Rastetter W; Molina A; White CA Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532 [TBL] [Abstract][Full Text] [Related]
19. Biologic therapies for inflammatory eye disease. Lim L; Suhler EB; Smith JR Clin Exp Ophthalmol; 2006; 34(4):365-74. PubMed ID: 16764659 [TBL] [Abstract][Full Text] [Related]